Invention Grant
US09593118B2 Xanthine-substituted alkynyl carbamates/reverse carbamates as A2B antagonists
有权
黄嘌呤取代的炔基氨基甲酸酯/反向氨基甲酸酯作为A2B拮抗剂
- Patent Title: Xanthine-substituted alkynyl carbamates/reverse carbamates as A2B antagonists
- Patent Title (中): 黄嘌呤取代的炔基氨基甲酸酯/反向氨基甲酸酯作为A2B拮抗剂
-
Application No.: US15094903Application Date: 2016-04-08
-
Publication No.: US09593118B2Publication Date: 2017-03-14
- Inventor: Robert D. Thompson , Anthony Beauglehole , Guoquan Wang
- Applicant: Lewis and Clark Pharmaceuticals, Inc.
- Applicant Address: US VA Charlottesville
- Assignee: Lewis and Clark Pharmaceuticals, Inc.
- Current Assignee: Lewis and Clark Pharmaceuticals, Inc.
- Current Assignee Address: US VA Charlottesville
- Agency: Vance Intellectual Property, PC
- Main IPC: C07D473/06
- IPC: C07D473/06 ; A61K31/522
Abstract:
The present invention provides xanthine-substituted alkynyl carbamates/reverse carbamates and derivatives thereof and pharmaceutical compositions containing the same that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
Public/Granted literature
- US20160297819A1 XANTHINE-SUBSTITUTED ALKYNYL CARBAMATES/REVERSE CARBAMATES AS A2B ANTAGONISTS Public/Granted day:2016-10-13
Information query
